Allogene Therapeutics
Allogene Therapeutics Raises $325M in Series E
Allogene Therapeutics Raises $325M in Series E
Allogene Therapeutics has successfully raised $325M in a Series E at a $3.9B valuation led by TPG, Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California.
Company Overview
Allogene Therapeutics is a Biotech company headquartered in 210 East Grand Avenue, South San Francisco, CA 94080, founded in 2017 with 700+ employees.
Allogeneic CAR T therapy developer
Fundraising Details
- Amount Raised: $325M
- Round Type: Series E
- Valuation: $3.9B
- Date: 2024-04-15
- Investors: TPG, Gilead Sciences, Pfizer, Frazier Healthcare Partners, University of California
About Allogene Therapeutics
Allogeneic CAR T therapy developer The company is positioned in the Biotech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: 210 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2017
- Team Size: 700+
- Industry: Biotech
What This Means
This funding round demonstrates strong investor confidence in Allogene Therapeutics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. Allogene Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $3.9B valuation marks an important milestone for Allogene Therapeutics, positioning the company among notable players in the Biotech industry.
Looking Ahead
With this new capital, Allogene Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
This fundraising news was reported on 2024-04-15. For more information about Allogene Therapeutics, visit their headquarters at 210 East Grand Avenue, South San Francisco, CA 94080.
Company Info
Share
Related Reports
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Ema Raises $77M Series B to Expand Its Enterprise AI Employee Platform
Ema raised a $77 million Series B led by Creaegis, bringing total funding to $140 million as it scales AI agents across enterprise workflows.
Chamelio Raises $26M Series A for AI-Native Legal Operations
Chamelio raised a $26 million Series A led by Entrée Capital to replace legacy contract-management systems with agentic legal operations.
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free